Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Protein drink study aims to unlock appetite secrets

NCT ID NCT07534020

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This pilot study is testing how different protein beverages affect amino acid levels and appetite hormones in healthy adults. Twenty-four participants will try several drinks in a random order. The goal is to see which drink leads to the best changes in appetite-related signals.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
proprietary protein beverages
What this could lead to
If successful, this could help design better protein drinks for appetite control or nutrition.
What could go wrong
This is a very small, early pilot study in healthy people, so results may not apply to the general population or lead to any health claims.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

24 people

The number who actually took part.

Started

Apr 2026

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Males and females, ≥20 to ≤50 years of age. 2. Body mass index (BMI( ≥18.5 and \<25.0 kg/m2. 3. Self-reported regular consumer (≥5 days/week) of breakfast. 4. Women who are either pre- or post-menopausal. Premenopausal women that are not using hormonal contraceptives must have a history of regular menstrual cycles (21-35 d per cycle or at the investigator's discretion) for at least 3 months prior. 5. Willing to use personal smart phone and capable of downloading the Cronometer app for diet records. 6. Willing to adhere to all study procedures, including lifestyle considerations, and sign forms providing informed consent to participate in the study and authorization to release relevant protected health information to the Clinical Investigator. Exclusion Criteria: 1. Is currently following, or planning to be on, a weight loss regimen at any time prior to or during the study. 2. Weight loss or gain \>4.5 kg within 90 days. 3. History of gastrointestinal surgery for weight reducing purposes. 4. History of an eating disorder (e.g., anorexia nervosa or bulimia nervosa, binge eating) or extreme dietary habits (e.g., ketogenic, very high protein, very high fiber, vegan, vegetarian) at the discretion of the Clinical Investigator. 5. History of unconventional sleep patterns (e.g., night shift) or a diagnosed sleep disorder or chronic medical condition that may impact appetite (in the judgment of the Investigator). 6. Use of tobacco/nicotine products (e.g., cigarette smoking, vaping, chewing tobacco) within 12 months. 7. Use of hemp/marijuana products within 60 days. Occasional use (e.g., once or twice a month) within 60 days is allowed. 8. Unstable use of any prescription medication, where stable use is defined as no change in dose or medication type within 90 days. 9. Unstable use (initiation or change in dose) within 30 days of hormonal contraceptives. 10. Use of any dietary supplements, except for a conventional once daily multivitamin/mineral supplement. 11. Recent history of (within 12 months) or strong potential for alcohol or substance abuse. 12. Exposed to any non-registered drug product within 30 days prior. 13. A score of \<7 on the Vein Access Scale Assessment. 14. History or presence, on the basis of the medical history or screening labs, of clinically important cardiac, renal, hepatic, endocrine (including diabetes mellitus), pulmonary, gastrointestinal, biliary, pancreatic, or neurological disorders that may affect the participant's ability to adhere to the study protocol and/or affect study outcomes, in the judgment of the Investigator. 15. Uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg). 16. Known allergy to any ingredients contained in the study product or study foods. 17. Any signs or symptoms of active infection of clinical relevance (e.g., urinary tract or respiratory) within 5 days. 18. History or presence of cancer in the prior 2 years, except for nonmelanoma skin cancer. 19. History of any major trauma or major surgical event within 2 months. 20. Female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential with unstable use (initiation or change in dose within 30 days) of sex hormones for contraception. 21. An employee or representative who has a financial interest in Shaklee Corporation. 22. Any condition the Investigator believes would interfere with the participant's ability to provide informed consent or comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Biofortis Clinical Research

    Addison, Illinois, 60101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.